Insilico Medicine's AI-designed drug clears Phase IIa trial
ISM001-055 is the first drug both designed by AI and targeting an AI-discovered disease target to post positive mid-stage results.
MVMara Vidović
Published 9 Jul 2026, 08:43Updated 28 Jul 2026, 20:331 min read
Insilico Medicine's ISM001-055 has posted positive Phase IIa trial results, notable as the first drug to be both AI-designed and aimed at a disease target AI itself discovered.
The company reports over 60% time reduction from project initiation to preclinical candidate compared to traditional drug discovery timelines.
Source: Tech Times
